

Peter A Merkel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2052517/peter-a-merkel-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301
papers

20,597
citations

68
h-index

137
g-index

327
ext. papers

25,997
ext. citations

6.8
avg, IF

6.32
L-index

#	Paper	IF	Citations
301	Patient Perceptions and Preferences Regarding Telemedicine for Rheumatologic Care during the COVID-19 Pandemic.. <i>Arthritis Care and Research</i> , 2022 ,	4.7	1
300	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	2
299	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	12
298	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	8
297	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	3
296	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	13
295	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.. <i>BMJ Open</i> , 2022 , 12, e050507	3	1
294	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.. <i>BMJ, The</i> , 2022 , 376, e064604	5.9	3
293	Response to: Correspondence on '2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis' by Joanna C Robson and '2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis' by Paul Sappich.. <i>Annals of the Rheumatic Diseases</i> , 2022 , 71, 1911-1912	2.4	3
292	The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152010	5.3	4
291	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152021	5.3	
290	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022 , 11, e27273	2.1	
289	Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2021 , 73, 1372-1378	4.7	3
288	Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain. <i>Arthritis Care and Research</i> , 2021 , 73, 1425-1429	4.7	1
287	Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease. <i>Arthritis Care and Research</i> , 2021 ,	4.7	2
286	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1370-1370	5.3	0
285	Pulmonary Involvement in Primary Systemic Vasculitides. <i>Rheumatology</i> , 2021 ,	3.9	2

284	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. <i>Patient</i> , 2021 , 14, 699-710	3.7	4
283	Diagnostic delays in vasculitis and factors associated with time to diagnosis. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 184	4.2	4
282	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021 , 3, 404-412	3.5	4
281	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021 , 3, 381-389	3.5	5
280	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 640-643	5.3	2
279	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2021 , 73, 1088-1105	4.7	14
278	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1366-1383	8.5	37
277	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1349-1365	9.5	34
276	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. <i>Arthritis and Rheumatology</i> , 2021 , 73, 512-519	9.5	15
275	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
274	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021 , 48, 603-607	4.1	29
273	Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. <i>Rheumatology</i> , 2021 , 60, 2246-2255	3.9	8
272	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021 , 3, 17-24	3.5	5
271	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021 , 108, 84-99	11	8
270	Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	0
269	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021 , 384, 599-609	59.2	109
268	Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra. <i>Journal of Neurology</i> , 2021 , 268, 2995-2999	5.5	1
267	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1089	9.5	

266	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1384-1393	9.5	6
265	Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1703-1712	9.5	5
264	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis Care and Research</i> , 2021 , 73, 1061-1070	4.7	2
263	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1071-1087	4.7	12
262	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1134-1138	5.3	2
261	Eosinophils in Health and Disease: A State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2694-2707	7.4	15
260	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 114-118	2.2	2
259	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020 , 21, 362	2.8	7
258	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1741-1747	9.5	15
257	Harnessing health plan enrollee data to boost membership in patient-powered research networks. <i>BMC Health Services Research</i> , 2020 , 20, 462	2.9	2
256	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. <i>BMC Medical Research Methodology</i> , 2020 , 20, 58	4.7	10
255	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1114-1130	5.3	3
254	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020 , 382, 622-631	59.2	211
253	Clinical associations of renal involvement in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102495	13.6	23
252	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020 , 59, 487-494	3.9	27
251	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020 , 59, e1-e23	3.9	57
250	Comment on: Derivation of an angiographically based classification system in Takayasu's arteritis: reply. <i>Rheumatology</i> , 2020 , 59, 1184-1185	3.9	0
249	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. <i>American Journal of Pathology</i> , 2020 , 190, 1438-1448	5.8	4

248	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020 , 5,	9.9	2
247	Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network 2020 , 2020, 1220-1229	0.7	1
246	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. <i>IMB Research Protocols</i> , 2020 , 9, e16664	2	34
245	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e17231	7.6	5
244	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 576-581	5.3	6
243	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 667-676	9.5	13
242	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments. <i>Arthritis Care and Research</i> , 2020 , 72, 1296-1304	4.7	11
241	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. <i>Arthritis Care and Research</i> , 2020 ,	4.7	7
240	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 167-171	2.3	2
239	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020 , 2, 662-671	3.5	24
238	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1314-1325	5.3	6
237	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 71	51.1	117
236	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020 , 11, 2053	8.4	3
235	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 99-107	4.1	28
234	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020 , 59, 1118-1127	3.9	12
233	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 1001-1010	4.1	9
232	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1615-1624	4.7	32
231	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 283-291	4.3	27

230	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 126-134	2.2	1
229	Patient involvement in medical research: what patients and physicians learn from each other. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 21	4.2	18
228	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 952-963	9.5	46
227	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2170-2177	11.5	41
226	MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. <i>Cell Systems</i> , 2019 , 8, 380-394.e4	10.6	38
225	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019 , 58, 2203-2211	3.9	21
224	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1888-1893	9.5	19
223	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1879-1887	9.5	15
222	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 594-602	8.6	11
221	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019 , 46, 1198-1201	4.1	4
220	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , 2019 , 10, 37-42	2.9	4
219	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019 , 46, 928-934	4.1	3
218	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
217	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 707-713	5.3	21
216	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019 , 105, 102302	15.5	13
215	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. <i>Journal of Rheumatology</i> , 2019 , 46, 1415-1420	4.1	5
214	Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	17
213	Ascending Aortic Aneurysm Secondary to Isolated Noninfectious Ascending Aortitis. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 186-194	1.1	2

212	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
211	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 117, 40-44	2.2	7
210	Patients' experiences with Behçet's syndrome: structured interviews among patients with different types of organ involvement. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 121, 28-34	2.2	3
209	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018 , 57, 322-328	3.9	20
208	Comparison of magnetic resonance angiography and F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1165-1171	2.4	53
207	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1114-1121	9.5	29
206	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018 , 57, 639-650	3.9	13
205	Cross-phenotype analysis of Immunochip data identifies as a relevant for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 589-595	2.4	16
204	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 251-257	6.9	25
203	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1157-1164	2.4	24
202	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1448-1453	2.4	23
201	Metabolic pathways and immunometabolism in rare kidney diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1226-1233	2.4	41
200	Impact of vasculitis on employment and income. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 111, 58-64	2.2	4
199	F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 439-449	9.5	143
198	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2018 , 38, 675-682	3.6	28
197	Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis and Rheumatology</i> , 2018 , 70, 171-184	9.5	121
196	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018 , 140, 159-166	2.8	15
195	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018 , 13, e0205768	3.7	5

194	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. <i>Patient Related Outcome Measures</i> , 2018 , 9, 17-34	2.9	13
193	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2077-2086	9.5	7
192	Health-related outcomes of importance to patients with Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 111, 51-57	2.2	6
191	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 846-853	9.5	82
190	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 837-845	9.5	155
189	Infections and the risk of incident giant cell arteritis: a population-based, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1031-1035	2.4	35
188	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017 , 7, 43953	4.9	34
187	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 112	2.8	43
186	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1921-1932	59.2	416
185	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1750-1753	4.1	18
184	Reply. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1505-1506	9.5	
183	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. <i>Rheumatology</i> , 2017 , 56, 1154-1161	3.9	61
182	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 176-184	9.5	13
181	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1054-1066	9.5	85
180	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017 , 100, 64-74	11	43
179	Composition corporelle, fonction pulmonaire et perte progressive de masse osseuse chez l'adulte souffrant de mucoviscidose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 51-56	0.1	
178	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017 , 46, 231-238	4.6	10
177	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1933-1937	4.1	25

176	Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise. <i>Journal of Rheumatology</i> , 2017 , 44, 1928-1932	4.1	16
175	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017 , 44, 1515-1521	4.1	24
174	Patient-reported outcomes in Takayasu's arteritis. <i>Presse Medicale</i> , 2017 , 46, e225-e227	2.2	2
173	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017 , 44, 1468-1475	4.1	33
172	Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2017 , 56, 1962-1969	3.9	26
171	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017 , 3, e000449	5.9	16
170	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017 , 44, 84-90	4.1	27
169	Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. <i>Arthritis Care and Research</i> , 2017 , 69, 1377-1383	4.7	10
168	The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 169-175	9.5	17
167	Patient-Reported Outcomes in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 140-148	6.9	16
166	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017 , 69, 1004-1010	4.7	10
165	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 185-193	9.5	33
164	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 11-18	2.3	190
163	Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 202-208	2.2	5
162	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 98-101	2.2	2
161	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e50	7.6	15
160	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017 , 44, 1529-1535	4.1	17
159	The association of vascular risk factors with visual loss in giant cell arteritis. <i>Rheumatology</i> , 2017 , 56, 524-528	3.9	9

158	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 475-82	5.3	73
157	Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2945-2952	9.5	48
156	Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1368-1374	2.6	18
155	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
154	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1700-10	9.5	86
153	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2016 , 43, 1559-65	4.1	39
152	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. <i>Journal of Rheumatology</i> , 2016 , 43, 1553-8	4.1	25
151	Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis. <i>Joint Bone Spine</i> , 2016 , 83, 207-11	2.9	11
150	Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. <i>Quality of Life Research</i> , 2016 , 25, 2109-16	3.7	34
149	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016 , 46, 48-51	2.3	20
148	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1166-9	2.4	123
147	The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. <i>Orphanet Journal of Rare Diseases</i> , 2016 , 11, 66	4.2	43
146	Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1711-20	9.5	69
145	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016 , 88, 6317-25	7.8	22
144	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016 , 43, 1078-84	4.1	20
143	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1975-88	27.4	74
142	Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1274-1277	4.5	7
141	Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab. <i>Journal of Drugs in Dermatology</i> , 2016 , 15, 359-62	2.2	4

140	Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. <i>New England Journal of Medicine</i> , 2015 , 372, 1510-8	59.2	157
139	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015 , 42, 1213-7	4.1	87
138	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1922-32	9.5	86
137	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015 , 26, 545-53	3.9	254
136	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015 , 42, 1209-12	4.1	50
135	Defining the nasal transcriptome in granulomatosis with polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2015 , 67, 2233-9	9.5	11
134	A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. <i>American Journal of Human Genetics</i> , 2015 , 96, 565-80	11	96
133	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2015 , 59, 43-52	15.5	5
132	Outcome measures for Takayasu's arteritis. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 32-7	5.3	23
131	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , 2015 , 42, 2436-41	4.1	14
130	Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. <i>Journal of Cystic Fibrosis</i> , 2015 , 14, 526-32	4.1	29
129	Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1111-7	10.2	46
128	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015 , 42, 2204-9	4.1	18
127	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015 , 42, 2465-9	4.1	26
126	Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 976-85	12.7	94
125	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015 , 54, 1351-9	3.9	32
124	Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 535-44	9.5	18
123	Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health. <i>Arthritis Care and Research</i> , 2015 , 67, 255-63	4.7	6

122	Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2457-65	9.5	9
121	Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015 , 10, e0121737	3.7	24
120	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 993-7	2.4	77
119	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1369-79	3.9	17
118	Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1361-8	9.5	60
117	Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2014 , 66, 428-32	9.5	19
116	Current status of outcome measure development in vasculitis. <i>Journal of Rheumatology</i> , 2014 , 41, 593-8	4.1	25
115	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1376-9	2.4	98
114	Outcome measures used in clinical trials for Behçet syndrome: a systematic review. <i>Journal of Rheumatology</i> , 2014 , 41, 599-612	4.1	41
113	Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, 583-6	8.6	52
112	Alcohol-induced vasculitis: case report and commentary. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, e42-3	4.5	4
111	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
110	In response: risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis. <i>Annals of Internal Medicine</i> , 2014 , 161, 230	8	0
109	Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. <i>Annals of Internal Medicine</i> , 2014 , 160, 73-80	8	100
108	Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. <i>Arthritis Care and Research</i> , 2014 , 66, 1731-9	4.7	22
107	The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire. <i>Rheumatology</i> , 2014 , 53, 1414-21	3.9	14
106	Causal attributions about disease onset and relapse in patients with systemic vasculitis. <i>Journal of Rheumatology</i> , 2014 , 41, 923-30	4.1	14
105	Updating the OMERACT filter: core areas as a basis for defining core outcome sets. <i>Journal of Rheumatology</i> , 2014 , 41, 994-9	4.1	19

104	Efficacy of remission-induction regimens for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2013 , 369, 417-27	59.2	446
103	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). <i>Clinical and Experimental Nephrology</i> , 2013 , 17, 619-621	2.5	129
102	Identification of multiple genetic susceptibility loci in Takayasu arteritis. <i>American Journal of Human Genetics</i> , 2013 , 93, 298-305	11	115
101	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
100	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1003-10	2.4	141
99	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1342-50	2.4	80
98	Polyarteritis Nodosa 2013 , 46-47		
97	L50. The future of international clinical trials in vasculitis. <i>Presse Medicale</i> , 2013 , 42, 637-41	2.2	2
96	Pregnancy outcomes among patients with vasculitis. <i>Arthritis Care and Research</i> , 2013 , 65, 1370-4	4.7	40
95	Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2457-68		102
94	Spinal gout presenting as acute low back pain. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2660		4
93	New features of disease after diagnosis in 6 forms of systemic vasculitis. <i>Journal of Rheumatology</i> , 2013 , 40, 1905-12	4.1	29
92	urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Rheumatology</i> , 2013 , 40, 674-83	4.1	28
91	Readability and suitability assessment of patient education materials in rheumatic diseases. <i>Arthritis Care and Research</i> , 2013 , 65, 1702-6	4.7	32
90	Illness perceptions and fatigue in systemic vasculitis. <i>Arthritis Care and Research</i> , 2013 , 65, 1835-43	4.7	40
89	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012 , 64, 273-9	4.7	34
88	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012 , 64, 351-7	4.7	41
87	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3420-9		57

86	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3463-71		27
85	Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. <i>PLoS ONE</i> , 2012 , 7, e30197	3.7	14
84	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1329-34	2.4	175
83	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. <i>Rheumatology</i> , 2012 , 51, 100-9	3.9	217
82	Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. <i>Journal of Rheumatology</i> , 2012 , 39, 303-9	4.1	41
81	Defining disease activity and damage in patients with small-vessel vasculitis. <i>Cleveland Clinic Journal of Medicine</i> , 2012 , 79 Suppl 3, S11-5	2.8	6
80	Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 424-33	5.3	16
79	Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011 , 57, 566-74	7.4	131
78	The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. <i>Journal of Rheumatology</i> , 2011 , 38, 1480-6	4.1	78
77	Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. <i>Journal of Rheumatology</i> , 2011 , 38, 1471-9	4.1	64
76	A woman with severe lupus nephritis and difficult to control diabetes mellitus. <i>Arthritis Care and Research</i> , 2011 , 63, 623-9	4.7	5
75	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011 , 63, 588-96	4.7	116
74	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Care and Research</i> , 2011 , 63, 1055-61	4.7	47
73	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2011 , 63, 1777-81	4.7	49
72	Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 863-4		188
71	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2495-503		50
70	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3988-97		48
69	Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 704	2.4	80

68	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 32-8	2.4	304
67	Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. <i>Journal of Rheumatology</i> , 2011 , 38, 1048-54	4.1	35
66	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 80-5	2.4	39
65	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 20736-41	11.5	58
64	Assessment of disease activity and progression in Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S86-91	2.2	51
63	Rituximab versus cyclophosphamide for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2010 , 363, 221-32	59.2	1713
62	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1744-50	2.4	114
61	Genetics of vasculitis. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 157-63	5.3	30
60	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. <i>Arthritis Care and Research</i> , 2010 , 62, 1166-73	4.7	148
59	Skin ulcers in a patient with Sjögren's syndrome. <i>Arthritis Care and Research</i> , 2010 , 62, 1040-6	4.7	4
58	Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. <i>Arthritis Care and Research</i> , 2010 , 62, 1639-45	4.7	66
57	Alpha ₁ -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3760-7		74
56	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009 , 36, 2356-61	4.1	32
55	Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. <i>Journal of Rheumatology</i> , 2009 , 36, 2362-8	4.1	26
54	Noninfectious ascending aortitis: staying ahead of the curve. <i>Journal of Rheumatology</i> , 2009 , 36, 2137-40	4.1	13
53	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1102-11		108
52	Clinical research for rare disease: opportunities, challenges, and solutions. <i>Molecular Genetics and Metabolism</i> , 2009 , 96, 20-6	3.7	242
51	Thromboembolic disease in vasculitis. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 41-6	5.3	65

50	Case records of the Massachusetts General Hospital. Case 31-2008. A 39-year-old man with chest pain, arthralgias, and a mediastinal mass. <i>New England Journal of Medicine</i> , 2008 , 359, 1603-14	59.2	5
49	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. <i>Arthritis and Rheumatism</i> , 2008 , 58, 15-25		1675
48	Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 746-753		39
47	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008 , 59, 699-705		85
46	Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007 , 56, 323-33		360
45	Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2789-97		343
44	Nutrient status of adults with cystic fibrosis. <i>Journal of the American Dietetic Association</i> , 2007 , 107, 2114-9		30
43	Outcome measures in systemic sclerosis: an update on instruments and current research. <i>Current Rheumatology Reports</i> , 2007 , 9, 151-7	4.9	49
42	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 605-17	2.4	394
41	Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 146, 621-30	8	345
40	Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. <i>Annals of Internal Medicine</i> , 2007 , 147, 611-9	8	181
39	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007 , 34, 501-9	4.1	38
38	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. <i>Journal of Rheumatology</i> , 2007 , 34, 1027-31	4.1	19
37	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007 , 34, 1194-200	4.1	58
36	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1357-71	4.1	26
35	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. <i>Journal of Rheumatology</i> , 2007 , 34, 2446-50	4.1	32
34	Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , 2005 , 142, 620-6	8	225
33	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 902-10		41

32	Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Arthritis and Rheumatism</i> , 2005 , 52, 2168-78		142
31	Guide to bone health and disease in cystic fibrosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1888-96	5.6	315
30	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005 , 32, 832-40	4.1	101
29	Scleroderma--developing measures of response. <i>Journal of Rheumatology</i> , 2005 , 32, 2477-80	4.1	14
28	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005 , 32, 2488-95	4.1	28
27	Hearing loss in Wegener's granulomatosis. <i>Otology and Neurotology</i> , 2004 , 25, 833-7	2.6	40
26	Diagnostic imaging in Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 31-7	5.3	162
25	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003 , 49, 819-25		27
24	Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. <i>Journal of Rheumatology</i> , 2003 , 30, 1630-47	4.1	97
23	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1309-18		326
22	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2410-20		223
21	Evaluation and treatment of vasculitis in the critically ill patient. <i>Critical Care Clinics</i> , 2002 , 18, 321-44	4.5	8
20	A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). <i>Arthritis and Rheumatism</i> , 2001 , 44, 912-20		337
19	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. <i>Arthritis and Rheumatism</i> , 2000 , 43, 226-31		135
18	Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. <i>Arthritis and Rheumatism</i> , 2000 , 43, 405-13		328
17	Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2488-92		41
16	Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 384-8		36
15	Rheumatic disease and cystic fibrosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1563-71		24

14	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998 , 41, 670-7		142
13	Drugs associated with vasculitis. <i>Current Opinion in Rheumatology</i> , 1998 , 10, 45-50	5.3	67
12	Measurement of functional status, self-assessment, and psychological well-being in scleroderma. <i>Current Opinion in Rheumatology</i> , 1998 , 10, 589-94	5.3	19
11	Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. <i>Annals of Internal Medicine</i> , 1997 , 126, 866-73	8	147
10	Heterotopic ossification in the setting of neuromuscular blockade. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1619-27		24
9	The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. <i>American Journal of Medicine</i> , 1996 , 101, 576-83	2.4	142
8	Cocaine-associated cerebral vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 1995 , 25, 172-83	5.3	92
7	Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate. <i>Journal of General Internal Medicine</i> , 1994 , 9, 679-83	4	31
6	Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major. <i>Pediatric Research</i> , 1993 , 33, 497-500	3.2	11
5	Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. <i>New England Journal of Medicine</i> , 1988 , 318, 809-14	59.2	187
4	Cocaine (Levamisole) Induced Vasculitis130-131		
3	Raynaud's Phenomenon34-35		
2	Small Vessel Vasculitis50-51		
1	Digital Ischemia in Systemic Sclerosis30-31		